Consultation outcome

Consultation on reviews of three merger undertakings and one market investigation Order

This consultation has concluded

Detail of outcome

The CMA has published, for consultation, its provisional decisions to release/revoke all of the remedies in question. Please see consultation on provisional decisions on reviews of three merger undertakings and one market investigation Order for more information on the consultation.

Feedback received

RECCo response to CMA

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email general.enquiries@cma.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Xoserve response to CMA

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email general.enquiries@cma.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Original consultation

Summary

The CMA is seeking views from interested stakeholders for its reviews of three merger remedies and one market investigation Order.

This consultation ran from
to

Consultation description

The CMA has decided to conduct reviews of the following CMA remedies: 

The CMA consulted on whether to launch reviews of a number of remedies in its portfolio in an invitation to comment published on 30 January 2023, which closed on 17 February 2023.

The purpose of these reviews is to determine whether, as a result of any change in circumstance, any of the remedies listed above are no longer appropriate and need to be varied, superseded or released. 

We are keen to receive relevant evidence from interested parties to help us reach a decision on whether there has been a relevant change in circumstances which means that the remedies listed above should be varied or released.

Respondents should provide their views supported with relevant evidence where possible, in writing to the CMA at the address below by 5pm on Monday 12 December 2023. We will then consider the views and evidence received before reaching and consulting on a provisional decision.

Further information on this review can be found on our reviews of three merger undertakings and one market investigation Order case page.

The CMA requests that all submissions be accompanied by a non-confidential version which the respondent would be willing to have published on the CMA website when we publish our provisional decision. 

Contact 

remedies.reviews@cma.gov.uk

Documents

Decision to launch reviews

Updates to this page

Published 21 November 2023
Last updated 19 March 2024 + show all updates
  1. Details of final outcome and feedback published

  2. First published.

Sign up for emails or print this page